Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried, et al.
JAMA Dermatology (2019) Vol. 156, Iss. 1, pp. 44-44
Open Access | Times Cited: 410

Showing 1-25 of 410 citing articles:

Atopic dermatitis
Sinéad Langan, Alan D. Irvine, Stephan Weidinger
The Lancet (2020) Vol. 396, Iss. 10247, pp. 345-360
Closed Access | Times Cited: 1274
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
Amy S. Paller, Elaine C. Siegfried, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 5, pp. 1282-1293
Open Access | Times Cited: 313
JAK inhibitors in the treatment of atopic dermatitis
Raj Chovatiya, Amy S. Paller
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 927-940
Open Access | Times Cited: 231
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
Amy S. Paller, Eric L. Simpson, Elaine C. Siegfried, et al.
The Lancet (2022) Vol. 400, Iss. 10356, pp. 908-919
Closed Access | Times Cited: 176
New treatments in atopic dermatitis
Neha Puar, Raj Chovatiya, Amy S. Paller
Annals of Allergy Asthma & Immunology (2020) Vol. 126, Iss. 1, pp. 21-31
Closed Access | Times Cited: 167
A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2
Carmen Riggioni, Pasquale Comberiati, Mattia Giovannini, et al.
Allergy (2020) Vol. 75, Iss. 10, pp. 2503-2541
Open Access | Times Cited: 141
The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults
Yael Renert‐Yuval, Ester Del Duca, Ana B. Pavel, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 1, pp. 148-163
Open Access | Times Cited: 115
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
Thanaporn Ratchataswan, Tina Banzon, Jacob P. Thyssen, et al.
The Journal of Allergy and Clinical Immunology In Practice (2021) Vol. 9, Iss. 3, pp. 1053-1065
Open Access | Times Cited: 105
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
Andrew Blauvelt, Emma Guttman‐Yassky, Amy S. Paller, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 3, pp. 365-383
Open Access | Times Cited: 78
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck, Mette Deleuran, Robert Bissonnette, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 3, pp. 393-408
Open Access | Times Cited: 76
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis
Amy S. Paller, Carsten Flohr, Michael J. Cork, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 6, pp. 596-596
Open Access | Times Cited: 63
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
Alexandro Chu, Melanie Wong, Daniel Rayner, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 6, pp. 1470-1492
Open Access | Times Cited: 57
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 45
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)
Antonio Torrelo, Barbara Rewerska, María Laura Galimberti, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 1, pp. 23-32
Open Access | Times Cited: 44
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
Marcus Maurer, Thomas B. Casale, Sarbjit S. Saini, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 1, pp. 184-194
Open Access | Times Cited: 36
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
Eric L. Simpson, Jonathan I. Silverberg, Margitta Worm, et al.
Journal of the American Academy of Dermatology (2024) Vol. 90, Iss. 6, pp. 1190-1199
Open Access | Times Cited: 19
New and Emerging Systemic Treatments for Atopic Dermatitis
Megan Newsom, Arjun M. Bashyam, Esther A. Balogh, et al.
Drugs (2020) Vol. 80, Iss. 11, pp. 1041-1052
Open Access | Times Cited: 120
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS
Jonathan I. Silverberg, Gil Yosipovitch, Eric L. Simpson, et al.
Journal of the American Academy of Dermatology (2020) Vol. 82, Iss. 6, pp. 1328-1336
Open Access | Times Cited: 105
Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis
Jonathan I. Silverberg, Jacob P. Thyssen, Kyle Fahrbach, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 9, pp. 1797-1810
Open Access | Times Cited: 98
Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis
Doreen Siegels, Annice Heratizadeh, Susanne Abraham, et al.
Allergy (2020) Vol. 76, Iss. 4, pp. 1053-1076
Open Access | Times Cited: 95
Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity
Takashi Nomura, Jianni Wu, Kenji Kabashima, et al.
The Journal of Allergy and Clinical Immunology In Practice (2020) Vol. 8, Iss. 6, pp. 1840-1852
Closed Access | Times Cited: 93
Tape strips from early‐onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin
Ana B. Pavel, Yael Renert‐Yuval, Jianni Wu, et al.
Allergy (2020) Vol. 76, Iss. 1, pp. 314-325
Open Access | Times Cited: 90
Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers
Helen He, Caroline Meyer Olesen, Ana B. Pavel, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 89
Nomenclature and clinical phenotypes of atopic dermatitis
Giampiero Girolomoni, Marjolein de Bruin‐Weller, Valéria Aoki, et al.
Therapeutic Advances in Chronic Disease (2021) Vol. 12
Open Access | Times Cited: 83
Management of inadequate response and adverse effects to dupilumab in atopic dermatitis
Shanthi Narla, Jonathan I. Silverberg, Eric L. Simpson
Journal of the American Academy of Dermatology (2021) Vol. 86, Iss. 3, pp. 628-636
Closed Access | Times Cited: 78
Page 1 - Next Page

Scroll to top